Benefits and risks of drug combination therapy for inflammatory bowel disease

doi:10.3877/cma.j.issn.2095-2015.2019.05.001

Abstract

Abstract:

At present, the pathogenesis of inflammatory bowel disease (IBD) is not completely clear. Although more and more biological agents are available, there are still difficulties in the treatment of IBD. In clinical practice, when conventional treatment is not effective, combining several drugs to treat IBD may be an important treatment strategy.But the combination of drugs may increase the risk of infection and tumor while improving the efficacy. Therefore, the application of combined therapy should be selected skillfully combined with the patient′s disease type, disease degree, lesion range, high risk factors and previous medication.

Key words: Inflammatory bowel disease, Ulcerative colitis, Crohn disease, Combination therapy

Zhi Li, Wensong Ge. Benefits and risks of drug combination therapy for inflammatory bowel disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2019, 09(05): 193-195.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2019.05.001

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2019/V09/I05/193

References 23

1	Marteau P, Probert CS, Lindgren S, et al.Combined oral and enema treatment with Pentasa(mesalazine)is superior to oral therapy alone in patients with extensive mild/moderate activeulcerative colitis: a randomised, double blind, placebo controlled study[J]. Gut, 2005, 54(7): 960-965.
2	D′Albasio G, Pacini F, Camarri E, et al.Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study[J]. Am J Gastroenterol, 1997, 92(7): 1143-1147.
3	Malchow H, Ewe K, Brandes JW, et al.European Cooperative Crohn′s Disease Study(ECCDS): results of drug treatment[J]. Gastroenterology, 1984, 86(2): 249-266.
4	Blaker PA, Arenas-Hernandez M, Smith MA, et al.Mechanism of allopurinol induced TPMT inhibition[J]. Biochem Pharmacol, 2013, 86(4): 539-547.
5	Smith MA, Blaker P, Marinaki AM, et al.Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol[J]. J Crohns Colitis, 2012, 6(9): 905-912.
6	Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy[J]. Eur J Gastroenterol Hepatol, 2001, 13(11): 1297-1301.
7	Mantzaris GJ, Sfakianakis M, Archavlis E, et al.A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis[J]. Am J Gastroenterol, 2004, 99(6): 1122-1128.
8	Mate-Jimenez J, Hermida C, Cantero-Perona J, et al.6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2000, 12(11): 1227-1233.
9	Ewe K, Press AG, Singe CC, Stufler M, et al.Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn′s disease[J]. Gastroenterology, 1993, 105(2): 367-372.
10	Vasudevan A, Raghunath A, Anthony S, et al.Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn′s Disease[J]. Dig Dis Sci, 2019, 64(6): 1622-1631.
11	Panaccione R, Ghosh S, Middleton S, et al.Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology, 2014, 146(2): 392-400.e3.
12	Kopylov U, Al-Taweel T, Yaghoobi M, et al.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn′s disease: a systematic review and meta-analysis[J]. J Crohns Colitis, 2014, 8(12): 1632-1641.
13	Feagan BG, McDonald JW, Panaccione R, et al.Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn′s disease[J]. Gastroenterology, 2014, 146(3): 681-688.e1.
14	Colman RJ, Rubin DT.Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease[J]. J Crohns Colitis, 2015, 9(2): 312-317.
15	Cortes X, Borras-Blasco J, Fernendez S, et al.Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine[J]. Int J Clin Pharmacol Ther, 2016, 54(2): 125-128.
16	Bots S, Gecse K, Barclay M, et al.Combination Immunosuppression in IBD[J]. Inflamm Bowel Dis, 2018, 24(3): 539-545.
17	Lowry PW, Weaver AL, Tremaine WJ, et al.Combination therapy with oral ta-crolimus(FK506)and azathioprine or 6-mer-captopurine for treatment-refractory Crohn′s disease perianal fistulae[J]. Inflamm Bowel Dis, 1999, 5(2): 239-245.
18	Tanida S, Mizoshita T, Nishie H, et al.Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis[J]. J Clin Med Res, 2015, 7(11): 884-889.
19	Chi LY, Zitomersky NL, Liu E, et al.The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease[J]. Inflamm Bowel Dis, 2018, 24(6): 1344-1351.
20	Colombel JF, Sandborn WJ, Panaccione R, et al.Adalimumab safety in global clinical trials of patients with Crohn′s disease[J]. Inflamm Bowel Dis, 2009, 15(9): 1308-1319.
21	Singh S, Facciorusso A, Dulai PS, et al.Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis[J]. Clin Gastroenterol Hepatol, 2019, S1542-3565(19)30255-1.
22	Deepak P, Sifuentes H, Sherid M, et al.T-cell non-Hodg-kin′s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha(TNF-α)in-hibitors: results of the REFURBISH study[J]. Am J Gastroenterol, 2013, 108(1): 99-105.
23	Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor ne-crosis factor alpha therapy for treatment of Crohn′s disease[J]. Expert Opin Drug Saf, 2016, 15(4): 493-501.

[1]	Lining Shang, Chengzhou Du, Gang Guo, Dehe Chen, Jie Wang, Peng Chen, Hongtao Li. Progress on the study of programmed cell death receptor 1 inhibitors for advanced gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(05): 376-381.
[2]	Jianming Zhang, Wenhui Ye, Tingyu Mou, Xiaoliang Lan, Haijun Deng. To analyze the recent complications of laparoscopic proctocolectomy ileal j-pouch anal anastomosis and their prevetion and treatment strategies [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 388-395.
[3]	Yuqing Qiao, Lei Shen, Linxiang Zhou, Xiangjie Li, Bo Yan. The effect of connective tissue growth factor monoclonal antibody on intestinal fibrosis in mice with chronic colitis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 125-131.
[4]	Xiao Qu, Liang Wang, Ping Lu, Bin He, Min Sun. Correlation analysis of inflammatory factors in peripheral blood and characteristics of Gut microbiota with the condition of patients with active Ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 466-470.
[5]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[6]	Tingting Chen, Xueliang Jiang, Jiali Yu, Jianlin Ke. Safety of stem cells in the treatment of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 193-198.
[7]	Jiali Yu, Xueliang Jiang. Application progress of biological agents from the perspective of therapeutic strategy transformation of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(03): 129-134.
[8]	Xiang Liao, Shuang Li, Yao Zeng. Analysis of research trends and hotspots of fecal microbiota transplantation from 2012 to 2021 [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 93-99.
[9]	Wensong Ge. Dual targeted therapy for the management of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 65-67.
[10]	Sucong Lyv, Guoqiang Zhong, Jin Li, Mingsong Li. Psychological problems associated with inflammatory bowel disease and its progress in diagnosis and treatment [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(01): 33-38.
[11]	Keyi Wei, Changqing Xu, Jing Yang. Application of nanomedicines in targeted therapy of biologics for inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(06): 367-372.
[12]	Xueliang Jiang, Jianlin Ke, Tingting Chen, Jiali Yu. Effects of different doses of bifidobacterium tetralogy viable tablets on intestinal flora imbalance in patients with mild and moderate active ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(05): 260-264.
[13]	Meng Wang, Dongyan Xu, Xiaoyu Zhang, Haijian Zhao. Analysis of anal function and quality of life in patients with inflammatory bowel disease associated with perianal diseases [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 224-227.
[14]	Xiuluo Fang, Taiyun Zhao, Xingjun Lu. Effect of Kangfuxin solution combined with mesalazine on expression of HMGB1, MCP-1, SOCS-3, and Beclin1 in patients with active ulcerative colitis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(03): 246-251.
[15]	Xin Ma, Meng Jin, Huijuan Ning, Wenwen Liu, Youzhe Gong, Yanling Zhang, Xuemei Zhong. Application of small intestinal capsule endoscopy in children with Crohn′s disease [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(03): 185-189.

Please choose a citation manager

Content to export